Physician profile
Kanwardeep Grewal
NPI 1104035468
$7,314.08
in general payments reported to CMS, 2019-2025
11 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.21 · 2021: $1,965 · 2022: $4,490 · 2023: $489 · 2024: $58.42 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $447 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $338 · Education: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.92 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $337.50 |
| Education | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,728.83 | 2021-2025 | |
| Allergan, INC. | $200.00 | 2021 | |
| Pfizer INC. | $124.99 | 2025 | |
| Sk Life Science, INC. | $53.96 | 2022 | |
| Ucb, INC. | $48.02 | 2022-2025 | Rystiggo |
| Jazz Pharmaceuticals INC. | $45.21 | 2019 | |
| Janssen Biotech, INC. | $31.52 | 2025 | |
| Janssen Pharmaceuticals, INC | $22.27 | 2022 | |
| Glaxosmithkline, LLC. | $20.40 | 2025 | Trelegy Ellipta |
| Alexion Pharmaceuticals, INC. | $19.70 | 2025 | Ultomiris |
| Lundbeck LLC | $19.18 | 2025 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kanwardeep Grewal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.